AstraZeneca's Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with chronic kidney disease, extending its lead over rival drugs in the class.

Forxiga is so far only cleared for HFrEF in ... mechanisms of action there could be scope for combination use. AstraZeneca and Ionis add an EU green light to earlier approvals in the US and ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Rajeev Juneja, vice chairman and managing director of Mumbai, Indian-based drugmaker Mankind Pharma (NSE: MANKIND), today ...

AstraZeneca PLC (NASDAQ ... diabetes portfolio features innovative treatments such as SGLT2 inhibitors (e.g., FORXIGA), GLP-1 receptor agonists (e.g., Bydureon BCise), and DPP-4 inhibitors ...

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...